Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Breast 2Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 25Neoplasms 9Kidney Neoplasms 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Carcinoma, Medullary 4Carcinoma 4Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Pain 2Ovarian Neoplasms 2Liver Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Kidney Diseases 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × cabozantinib × Clear all
NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

Phase 1 Active not recruiting
914 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡